VIDEO: Recent approval ‘adds another option’ for patients with myelofibrosis

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

In the myeloproliferative neoplasm space, the most recent approval would probably be for myelofibrosis, and that was momelotinib in, it was either October or November of 2023. So that is the fourth JAK2 inhibitor approved in the US for the treatment of myelofibrosis, and that drug was approved irrespective of line of therapy and with the qualification of anemia, but not for the qualified by a degree of anemia or the need for transfusion dependence. It really adds another option for our patients, either upfront or second line to address their symptom and spleen burden with the potential to offset anemia.